History of MOG Antibody Serologic Testing In this review, we examine the history of serologic testing, the natural history of MOGAD and its clinical phenotypes, and our current knowledge of its pathophysiology, and summarize current and potential future therapies. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is now identified routinely owing to the development of widely commercially available cell-based assay (CBA) antibody testing. Disorders previously organized by shared clinical phenotype are now better defined by histopathology and clinical biomarkers, including advanced imaging, cerebrospinal fluid (CSF) testing, and serum and CSF autoantibodies. Our understanding of central nervous system (CNS) demyelinating diseases has evolved over time, with the recognition of stereotyped clinical phenotypes, improved histopathologic categorization, and more robust assays for identifying CNS-specific autoantibodies.